Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 70,723,214 | 115,038,771 | 32,878,926 | 51,639,109 | 61,556,925 | 331,836,945 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 70,723,214 | 115,038,771 | 32,878,926 | 51,639,109 | 61,556,925 | 331,836,945 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 159,305,553 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 172,531,392 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 70,723,214 | 115,038,771 | 32,878,926 | 51,639,109 | 61,556,925 | 331,836,945 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 378,725 | 2,090,669 | 3,205,975 | 3,312,682 | 4,952,174 | 13,940,225 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 95,299 | 104,653 | 38,049 | 742,082 | 258,491 | 1,238,574 |
| 11 | Total support. Add lines 7 through 10 | 347,015,744 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2021 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2021 |
(iii) Distributable Amount for 2021 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2021 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2021 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2021: | ||||
| a From 2016....... | ||||
| b From 2017....... | ||||
| c From 2018....... | ||||
| d From 2019....... | ||||
| e From 2020....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2021 distributable amount | ||||
|
i
Carryover from 2016 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2021 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2021 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2021, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2021. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2022. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2017..... | ||||
| b Excess from 2018..... | ||||
| c Excess from 2019..... | ||||
| d Excess from 2020..... | ||||
| e Excess from 2021..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART I, LINE 1 & PART III, LINE 1: | THE NEW YORK GENOME CENTER (NYGC) IS AN INDEPENDENT, NONPROFIT MEDICAL RESEARCH ORGANIZATION THAT SERVES AS A MULTI-INSTITUTIONAL HUB FOR GENOMIC RESEARCH. LEVERAGING OUR STRENGTHS IN WHOLE-GENOME SEQUENCING AND GENOMIC ANALYSIS, OUR MISSION IS THE ADVANCEMENT OF GENOMIC SCIENCE AND ITS APPLICATION TO NOVEL BIOMEDICAL DISCOVERIES. NYGC'S AREAS OF FOCUS INCLUDE THE DEVELOPMENT OF NOVEL COMPUTATIONAL AND EXPERIMENTAL METHODS IN GENOMICS AND DISEASE-FOCUSED RESEARCH. THE CENTER IS KNOWN INTERNATIONALLY FOR ENHANCING OUR UNDERSTANDING OF THE GENETIC BASIS OF CANCER, NEURODEGENERATIVE DISEASE (ALS, ALZHEIMER'S, FTD, PARKINSON'S AND HUNTINGTON'S), AND NEUROPSYCHIATRIC DISEASE (AUTISM, SCHIZOPHRENIA, BIPOLAR DISORDER). SINCE 2020, THE NYGC HAS ALSO DIRECTED ITS EXPERTISE TO COVID-19 RESEARCH. NYGC SERVES AS A NEXUS FOR COLLABORATION IN GENOMIC RESEARCH FOR THE NEW YORK COMMUNITY AND BEYOND, BUILDING ON THE COMBINED STRENGTHS OF FACULTY, MEMBER INSTITUTIONS, SCIENTIFIC WORKING GROUPS, AFFILIATE MEMBERS, AND INDUSTRY PARTNERS. NYGC'S GROWTH AND DEDICATION TO EXCELLENCE EMPOWERS THE CLINICAL AND SCIENTIFIC COMMUNITY WITH THE RESOURCES AND EXPERTISE TO ACCELERATE GENOMIC SCIENCE. THE NYGC TEAM, LED BY EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO TOM MANIATIS, PHD, INCLUDES SENIOR AND CORE FACULTY MEMBERS WHO HOLD JOINT APPOINTMENTS AT LEADING ACADEMIC INSTITUTIONS. THE FACULTY INCLUDES A NOBEL LAUREATE, SIX NATIONAL ACADEMY OF SCIENCES MEMBERS, THREE LASKER AWARD WINNERS, THREE NIH NEW INNOVATOR AWARD WINNERS, THREE NIH PATHWAY TO INDEPENDENCE AWARD WINNERS, AS WELL AS ONE NIH DIRECTOR'S TRANSFORMATIVE RESEARCH AWARDEE. NYGC HAS 16 MEMBER INSTITUTIONS AND 85 AFFILIATED SCIENTISTS IN ADDITION TO ITS INTERNAL SCIENTIFIC TEAM, ROBUST RESEARCH PROGRAMS, STATE-OF-THE-ART, NEXT GENERATION SEQUENCING/ANALYTICS CAPABILITIES, A CLINICAL LABORATORY CERTIFIED BY THE NEW YORK STATE DEPARTMENT OF HEALTH, AND A CUTTING-EDGE TECHNOLOGY INNOVATION TEAM. WE CONSIDER THE EXCHANGE OF IDEAS AMONG RESEARCHERS, BOTH WITHIN AND OUTSIDE THE CENTER, TO BE ESSENTIAL FOR THE UNDERSTANDING OF THE GENETIC BASIS OF HUMAN DISEASES, DEVELOPMENT OF NEW GENOMIC TECHNOLOGIES, AND THE ADVANCEMENT OF BASIC SCIENCE. NYGC STRIVES TO CHAMPION DIVERSITY, EQUITY, AND INCLUSION. IN ADDITION TO THE WORKPLACE THIS INCLUDES RESEARCH AND IN ITS APPLICATION TO CLINICAL CARE. A FUNDAMENTAL GOAL OF THE GENOME CENTER IS ADDRESSING THE LACK OF DIVERSITY WITHIN DATA SAMPLES AND SUBJECTS IN GENOMICS RESEARCH. NYGC IS ALSO COMMITTED TO EXPANDING DIVERSITY AS REFLECTED WITHIN THE CENTER'S BOARD OF DIRECTORS AND WITHIN THE FACULTY, STAFF, AND SCIENTIFIC RESEARCHERS. |
| FORM 990, PART III, LINE 4A & LINE 4B | NYGC IS COMMITTED TO ITS MISSION OF ADVANCING GENOMIC SCIENCE AND ITS APPLICATION TO NOVEL BIOMEDICAL THERAPEUTICS AND ACCELERATE ITS USE IN THE CLINICAL SETTING. RESEARCH AND FACULTY --------------------- NYGC ATTRACTS WORLD-CLASS SCIENTISTS AND IS COMMITTED TO SUPPORTING EMERGING YOUNG FACULTY. NYGC RESEARCHERS HAVE BACKGROUNDS IN SINGLE CELL GENOMICS, GENOMIC ENGINEERING, EVOLUTIONARY GENOMICS, TECHNOLOGY AND METHODS DEVELOPMENT, COMPUTATIONAL BIOLOGY AND BIOENGINEERING. MOST FACULTY MEMBERS HAVE JOINT APPOINTMENTS AT ONE OF NYGC'S PARTNER INSTITUTIONS TO PROMOTE PRODUCTIVE COLLABORATION, STRENGTHEN RESEARCH, ADVANCE ACADEMIC LEADERSHIP, AND BETTER UNDERSTAND HOW TO TREAT HUMAN DISEASES. THIS YEAR, THE CENTER RECRUITED THREE HIGHLY SOUGHT-AFTER EARLY-STAGE INVESTIGATORS INCLUDING: DR. GAMZE GURSOY BEGAN HER INDEPENDENT RESEARCH CAREER AT NYGC WITH A JOINT APPOINTMENT IN THE COLUMBIA UNIVERSITY DEPARTMENTS OF BIOMEDICAL INFORMATICS AND COMPUTER SCIENCE. SHE BRINGS A DIVERSE BACKGROUND INCLUDING HER INTEREST IN DEVELOPING TOOLS TO ANALYZE AND UNDERSTAND THE RELATIONSHIP BETWEEN GENOMIC STRUCTURE, VARIATION, AND MOLECULAR PHENOTYPES ASSOCIATED WITH DISEASES AND ADDING PRIVACY-PRESERVATION TO THESE MODELS AND DATASETS TO ENABLE INFERENCE FROM SENSITIVE GENOTYPIC AND PHENOTYPIC DATA WHILE PRESERVING PATIENT PRIVACY. AS A POSTDOC, DR. GURSOY WAS AWARDED A HIGHLY COMPETITIVE AND PRESTIGIOUS NIH/K99 "PATHWAY TO INDEPENDENCE AWARD" IN 2020 FROM THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI). CHENXU ZHU, PHD, IS A "MULTIOMICS" RESEARCHER AND HIS LAB FOCUSES ON APPLYING AN ARRAY OF INNOVATIVE GENOMIC METHODS, INCLUDING SINGLE-CELL TECHNOLOGIES, TO BETTER UNDERSTAND GENE REGULATION MECHANISMS IN HUMAN DEVELOPMENT AND DISEASE, PARTICULARLY CANCER. HE JOINED NYGC FROM THE SAN DIEGO BRANCH OF THE LUDWIG INSTITUTE FOR CANCER RESEARCH, WHERE HE SERVED AS A POSTDOCTORAL FELLOW IN ITS LABORATORY OF GENE REGULATION. DR. ZHU OBTAINED HIS PHD IN BIOCHEMISTRY AND MOLECULAR BIOLOGY FROM PEKING UNIVERSITY. HE ALSO HOLDS A JOINT APPOINTMENT AS ASSISTANT PROFESSOR AT NYGC MEMBER INSTITUTION WEILL CORNELL MEDICINE (WCM) IN THE DEPARTMENT OF PHYSIOLOGY AND BIOPHYSICS AND INSTITUTE FOR COMPUTATIONAL BIOMEDICINE. SANJA VICKOVIC, PHD, JOINED NYGC AS A CORE FACULTY MEMBER AND DIRECTOR OF NYGC'S TECHNOLOGY INNOVATION LAB. DR. VICKOVIC WORKED AT THE BROAD INSTITUTE OF MIT AND HARVARD, WHERE SHE WAS A WALLENBERG FELLOW IN DR. AVIV REGEV'S LAB. SHE OBTAINED HER PHD IN GENE TECHNOLOGY FROM THE KTH ROYAL INSTITUTE OF TECHNOLOGY, STOCKHOLM. DR. VICKOVIC IS AN EXPERIENCED AND ACCOMPLISHED ENGINEER AND AN INVENTOR OF THE SPATIAL TRANSCRIPTOMIC TECHNOLOGY CALLED "VISIUM" NOW COMMERCIALIZED BY 10X GENOMICS. SHE ALSO HAS TRAINING AND EXPERIENCE IN MATHEMATICS AND BIOLOGICAL SCIENCES. DR. VICKOVIC CURRENTLY HOLDS MULTIPLE JOINT APPOINTMENTS WHILE AT NYGC. SHE IS AN ASSISTANT PROFESSOR AT THE FU FOUNDATION SCHOOL OF ENGINEERING AND APPLIED SCIENCE AND THE HERBERT AND FLORENCE IRVING INSTITUTE FOR CANCER DYNAMICS AT COLUMBIA UNIVERSITY, AS WELL AS REMAINING A WALLENBERG ACADEMY FELLOW OF THE ROYAL SWEDISH ACADEMY OF SCIENCES AND THE ROYAL SWEDISH ACADEMY OF ENGINEERING SCIENCES AT UPPSALA UNIVERSITY. IN 2021, NYGC SCIENTISTS RECEIVED PRESTIGIOUS AWARDS FOR THEIR CONTRIBUTIONS TO PIONEERING RESEARCH, RELEASED FINDINGS FROM NEW STUDIES, AND DEVELOPED NEW GENOMIC TOOLS AND TECHNOLOGIES TO HELP ADVANCE PRECISION MEDICINE: DAN LANDAU, MD, PHD, RECEIVED A 2021 TOP 10 CLINICAL RESEARCH ACHIEVEMENT AWARD FOR HIS LAB'S BREAKTHROUGH TRANSLATIONAL RESEARCH IN DEVELOPING A HIGHLY SENSITIVE "LIQUID BIOPSY" BLOOD TEST FOR MONITORING OF CANCER PROGRESSION AND RELAPSE. DR. LANDAU ALSO LED THE TEAM THAT DEVELOPED A NEW MACHINE LEARNING TECHNIQUE THAT ANALYZES THE THOUSANDS OF DNA METHYLATION CHANGES DETECTED IN TUMOR CELLS -- AND INFERS WHICH ONES ARE LIKELY TO DRIVE TUMOR GROWTH. MARCIN IMIELINSKI, MD, PHD, IS AN AWARDEE OF THE 2021 PERSHING SQUARE SOHN PRIZE FOR YOUNG INVESTIGATORS IN CANCER RESEARCH. THE AWARD IS TO SUPPORT HIS PROJECT TO EXPLAIN WHY CERTAIN ACRAL MELANOMAS (WHICH OCCUR ON THE HANDS AND FEET) AND OTHER SIMILAR CANCERS WITH FEW SMALL MUTATIONS RESPOND TO IMMUNOTHERAPY BY EXAMINING A NOVEL CLASS OF GENETIC ALTERATIONS CALLED TYFONAS. THIS STUDY CAN TRANSFORM THE BASIC UNDERSTANDING OF CANCER EVOLUTION AND PROVIDE EVIDENCE FOR A WHOLE GENOME SEQUENCING IMMUNOTHERAPY BIOMARKER TO HELP NAVIGATE THE BEST COURSE FOR PATIENT TREATMENT. DR. IMIELINSKI ALSO LED THE MULTI-INSTITUTIONAL CANCER GENOMICS RESEARCH TEAM THAT RELEASED FINDINGS FROM A COMPREHENSIVE WHOLE-GENOME SEQUENCING STUDY OF A KEY SUBSET OF LUNG ADENOCARCINOMA (LUAD). THE TEAM'S REPORT DETAILS THEIR UNCOVERING OF STRUCTURAL GENETIC VARIANTS THAT MAY BE POTENTIAL NEW BIOMARKERS AND THERAPEUTIC TARGETS FOR LUAD, THE MOST COMMON LUNG MALIGNANCY AND A LEADING CAUSE OF CANCER DEATH IN THE U.S. RAHUL SATIJA, PHD, LED THE TEAM THAT DEVELOPED MIXSCAPE, A NEW COMPUTATIONAL TOOL TO INTERPRET EXPERIMENTS THAT COMBINE THE USE OF CRISPR TO PERTURB GENES ALONG WITH MULTIMODAL SINGLE-CELL SEQUENCING TECHNOLOGIES. THIS NEW TOOL HELPED TO IDENTIFY A NEW MOLECULAR MECHANISM FOR THE REGULATION OF IMMUNE CHECKPOINT PROTEINS THAT GOVERN THE IMMUNE SYSTEM'S ABILITY TO IDENTIFY AND DESTROY CANCER CELLS. NEVILLE SANJANA, PHD, RECEIVED A 2021 GRANT FROM THE SIMONS FOUNDATION (SFARI) TO SUPPORTS A PROJECT TO DEPLOY CRISPR AND OTHER TECHNOLOGIES TO UNCOVER BIOMARKERS FOR AUTISM GENE THERAPY. HEMALI PHATNANI, PHD IS A 2021 RECIPIENT OF THE NIH DIRECTOR'S TRANSFORMATIVE RESEARCH AWARD, PART OF THE NIH'S HIGH-RISK, HIGH-REWARD PROGRAM TO PROMOTE EXCEPTIONALLY INNOVATIVE OR UNCONVENTIONAL RESEARCH PROJECTS WITH THE POTENTIAL TO CREATE OR OVERTURN FUNDAMENTAL PARADIGMS. DR. PHATAMI WAS ALSO AWARDED A DEFENSE DEPT GRANT TO STUDY ALS-FRONTOTEMPORAL DEMENTIA. ADDITIONAL ACCOMPLISHMENTS IN 2021 INCLUDE: OVER THE PAST YEAR, NYGC HAS MADE GREAT PROGRESS IN CORE RESEARCH AREAS UNDER THE LEADERSHIP OF THE NEW YORK GENOME CENTER'S EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO, TOM MANIATIS. IN 2021, DR. MANIATIS WAS NAMED TO NEW YORK'S FIRST "CITY & STATE LIFE SCIENCES POWER 50" LIST, HIGHLIGHTING KEY INDIVIDUALS DRIVING THE LIFE SCIENCE SECTOR'S GROWTH IN NEW YORK. NYGC FACULTY PUBLISHED OVER 75 STUDIES IN HIGH-IMPACT SCIENTIFIC JOURNALS THAT PROVIDED NEW INSIGHTS INTO DISEASE MECHANISMS. NYGC RESEARCHERS HAVE DEVELOPED MANY INNOVATIVE GENOMIC TECHNOLOGIES AND NEW COMPUTATIONAL APPROACHES THAT ARE SHARED WIDELY WITH THE SCIENTIFIC COMMUNITY. CANCER: THE GENOME CENTER CANCER GROUP (GCCG), LED BY HAROLD VARMUS, MD, NYGC AND WEILL CORNELL MEDICINE, AND CHARLES SAWYERS, MD, MEMORIAL SLOAN KETTERING CANCER CENTER, IS COMPOSED OF CLINICIANS AND CANCER RESEARCHERS FROM NYGC'S MEMBER INSTITUTIONS, INCLUDING 10 NCI-DESIGNATED CANCER CENTERS. NYGC'S COLLABORATIVE CANCER INITIATIVE, POLYETHNIC-1000 (P-1000), WAS LAUNCHED IN 2018 TO ADVANCE CANCER GENOMICS IN UNDERREPRESENTED POPULATIONS. IN THE PAST YEAR, THE PROGRAM HAS APPOINTED TWO DISTINGUISHED CANCER AND ETHNICITY SCHOLARS, ONYINYE BALOGUN, MD, AND MELISSA B. DAVIS, PHD, ESTEEMED HEALTH DISPARITIES RESEARCHERS AT WEILL CORNELL MEDICINE WHO PROVIDE OVERSIGHT OF THE CONDUCT AND COORDINATION OF P-1000'S NEXT PHASE OF RESEARCH ACTIVITIES. DR. DAVIS RECENTLY AUTHORED A "SCIENCE & SOCIETY" ESSAY IN TRENDS IN CANCER. ADDITIONALLY, THE VERY RARE CANCER CONSORTIUM (VRCC) IS A RESEARCH COHORT FOCUSED ON UNDERSTANDING THE GENETIC CAUSES OF RARE, UNDERSTUDIED CANCERS AND LEVERAGES THE COMBINED EXPERTISE FROM INSTITUTIONS ACROSS NEW YORK CITY. THROUGH A NETWORK OF 20 MEMBER INSTITUTIONS, THIS PROJECT AIMS TO COLLECT SAMPLES OF VERY RARE CANCERS IN SUFFICIENT NUMBERS TO PROVIDE ANSWERS TO IMPORTANT SCIENTIFIC QUESTIONS, BUILD RESEARCH COHORTS, AND REDUCE THE TOLL TAKEN BY UNDERSTUDIED DISEASES. NEURODEGENERATIVE DISEASE: HEMALI PHATNANI, PHD, CORE FACULTY MEMBER AND DIRECTOR OF THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE AT NYGC, CONVENED THE THIRD NYGC ALS CONSORTIUM BIANNUAL MEETING IN WHICH ONE HUNDRED RESEARCHERS AND CLINICIANS, FROM 40+ GLOBAL MEMBER INSTITUTIONS, SHARED THE LATEST IN ALS GENOMICS RESEARCH AND CELEBRATED MILESTONE ACCOMPLISHMENTS INCLUDING CREATING ONE OF THE LARGEST ALS DATA COHORTS IN THE WORLD, EMPOWERING AN INTEGRATED GLOBAL APPROACH TO ADVANCE NEW TREATMENTS AND EFFECTIVE THERAPIES FOR THIS COMPLEX DISEASE. |
| FORM 990, PART III, LINE 4A | NEUROPSYCHIATRIC DISEASE: DR. THOMAS LEHNER, NYGC'S SCIENTIFIC DIRECTOR FOR NEUROPSYCHIATRIC DISEASE, LEADS NYGC'S NEUROPSYCHIATRIC DISEASE SCIENTIFIC WORKING GROUP. A KEY PROJECT THE GROUP IS DEVELOPING IS GEMMA (GENOMIC MEDICINE FOR MENTAL HEALTH AVANCEMENT). GEMMA IS A NEW YORK STATE-WIDE PRECISION PSYCHIATRY PLATFORM THAT INTEGRATES DIAGNOSTIC, DEMOGRAPHIC, AND PATIENT CARE DATA WITH GENOMIC DATA AND OTHER MEDICAL RECORDS FOR SCIENTIFIC DISCOVERY, CLINICAL VALIDATION, AND TRANSLATIONAL IMPLEMENTATION. THIS UNPRECEDENTED RESOURCE WOULD RAPIDLY DEEPEN THE KNOWLEDGE BASE OF DIVERSE BIOMARKERS AND GENETIC FACTORS DRIVING NEUROPSYCHIATRIC DISEASE ENABLING A TRANSFORMATIVE EXPANSION OF THE PREDICTIVE AND DIAGNOSTIC VALUE OF GENOMIC TESTS, CLINICALLY ACTIONABLE FINDINGS, THERAPEUTIC DEVELOPMENT, AND PERSONALIZED TREATMENT GUIDELINES BASED ON INDIVIDUAL GENETIC MAKEUP AND MACHINE LEARNING-BASED DATA MINING WHICH WILL VASTLY IMPROVE PATIENT EXPERIENCE AND OUTCOMES. NYGC CHIEF DIAGNOSTIC OFFICER VAIDEHI JOBANPUTRA, PHD, FACMG, IS A MEMBER OF THE INVESTIGATIVE TEAM THAT CONDUCTED WHOLE GENOME SEQUENCING ANALYSIS OF 200+ FAMILIES THAT INCLUDED INDIVIDUALS WITH SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS. BASED ON THEIR ANALYSIS, THE TEAM IDENTIFIED MORE FINELY TARGETED DIAGNOSES FOR MANY OF THESE INDIVIDUALS, AS WELL AS UNCOVERED BIOMARKERS REGARDING TOLERANCE/RESISTANCE TO ANTIPSYCHOTIC TREATMENTS. THE TEAM NOTES THAT WHOLE GENOME SEQUENCING CAN PLAY A POWERFUL ROLE IN THE SETTING OF BOTH RESEARCH AND GENETIC COUNSELING FOR INDIVIDUALS WITH SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS AND THEIR FAMILIES. THE STUDY, DRAWING FROM PARTICIPANTS AROUND THE GLOBE, WAS PUBLISHED IN MOLECULAR PSYCHIATRY IN 2021. COVID-19: IN 2020, NYGC ESTABLISHED THE COVID-19 GENOMICS RESEARCH NETWORK (CGRN), A MULTIDISCIPLINARY CONSORTIUM TO SUPPORT GLOBAL COVID-19 GENOMICS RESEARCH COLLABORATION AND BUILD AN INFORMATION-SHARING DATABASE. THIS RESOURCE HELPS SUPPORT THE ONGOING EFFORTS TO IMPROVE THE TREATMENT OF PATIENTS AND BETTER UNDERSTAND THE EVOLUTION OF THE VIRUS, AS WELL AS THE LONG-TERM IMPACT ON POPULATION HEALTH. ADDITIONALLY, NYGC'S CLINICAL LABORATORY CONDUCTED COVID-19 TESTING FOR VARIOUS HEALTHCARE ENTITIES AND THE RESEARCH STAFF CONTRIBUTED TO VIRAL SURVEILLANCE EFFORTS THROUGHOUT NEW YORK AND NEW JERSEY WITH THE GOAL OF IDENTIFYING NEW VIRAL VARIANTS THAT INCREASE THE SPREAD OF THE PATHOGEN. THESE EFFORTS RESULTED IN SEVERAL PUBLICATIONS. CLINICAL LABORATORY: NYGC'S CLINICAL LABORATORY HAS LENT ITS INFRASTRUCTURE AND EXPERTISE TO SEVERAL LARGE INITIATIVES IN CLINICAL GENOMICS, INCLUDING PARTNERING WITH ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI LED NYCKIDSEQ PROJECT AS PART OF THE NHGRI, NCI, AND NIMHD FUNDED CLINICAL SEQUENCING EVIDENCE-GENERATING RESEARCH (CSER) CONSORTIUM. THIS EFFORT PRIORITIZES GENOME SEQUENCING OF HISTORICALLY UNDERREPRESENTED PATIENT POPULATIONS TO IMPROVE CLINICAL OUTCOMES AND STUDY THE EFFECTIVENESS OF INTEGRATING GENOME SEQUENCING INTO CLINICAL CARE AND DEVELOP BEST PRACTICES FOR DISCOVERY, INTERPRETATION, RETURN OF RESULTS, AND HEALTHCARE UTILIZATION. IN ADDITION, THE NYGC CLINICAL LABORATORY IS CURRENTLY COLLABORATING WITH WEILL CORNELL MEDICINE, NEWYORK-PRESBYTERIAN HOSPITAL, AND ILLUMINA ON A PRECISION MEDICINE COLLABORATION IN CANCER, CARDIOLOGY, ENDOCRINOLOGY, AND NEUROLOGY TO ASSESS AND IMPROVE THE VALUE OF CLINICAL WHOLE GENOMES WITH AIMS OF RETURNING CLINICALLY ACTIONABLE RESULTS, INTEGRATING ELECTRONIC HEALTH RECORDS, DEVELOPING NOVEL POLYGENIC RISK SCORES, AND UNDERSTANDING THE ROLE OF GENETICS IN THERAPEUTIC RESPONSES. RESEARCH SEQUENCING ------------------- NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST SIX YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 82,000 WHOLE GENOME SAMPLES. NYGC HAS FIVE NOVASEQ SYSTEMS SEQUENCERS, WITH THE CAPACITY TO SEQUENCE THOUSANDS OF GENOMES A YEAR. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. NYGC'S RESEARCH SEQUENCING LAB, LED BY SOREN GERMER, PHD, SENIOR VICE PRESIDENT OF GENOME TECHNOLOGIES, PROCESSED MORE THAN 14,000 SAMPLES IN 2021, INCLUDING 4,552 WHOLE GENOME SEQUENCING SAMPLES (GERMLINE AND CANCER), 5,787 COVID VIRAL SAMPLES, 3,341 TRANSCRIPTOME (RNA) SEQUENCING SAMPLES. IN 2021 THE PRODUCTION SEQUENCING LAB WAS AWARDED NEW CONTRACTS FROM NHLBI FOR A TOTAL OF UP TO $5,640,230. NYGC ALSO PURCHASED TWO NEW SEQUENCING INSTRUMENTS IN 2021; ONE INSTRUMENT ADDS LONG READ CAPACITY TO THE CENTER'S SEQUENCING MENU, THE OTHER PROMISES SUBSTANTIALLY REDUCED REAGENT COSTS FOR HIGH-THROUGHPUT APPLICATIONS AND HAS CREATED A LOT OF EXCITEMENT IN THE GENOMICS COMMUNITY. AS ONE OF THE FEW EARLY ADOPTERS OF THIS TECHNOLOGY, NYGC IS WORKING INTENSIVELY TO ENABLE THIS TECHNOLOGY FOR A RANGE OF APPLICATIONS. IN 2021, NYGC CONTINUED TO EXPAND ITS OPERATIONAL FOCUS ON SINGLE-CELL GENOMICS, MAKING AVAILABLE TO THE RESEARCH COMMUNITY THROUGH FUNCTIONAL GENOMIC COLLABORATIONS NEW CUTTING-EDGE TECHNIQUES INVENTED IN THE CENTER'S INNOVATION LAB. THESE INCLUDE CITE-SEQ, ASAP-SEQ, DOGMA-SEQ AS WELL AS THE 10X MULTIOME ASSAY, TECHNIQUES THAT ALLOW SIMULTANEOUS MEASUREMENT IN THOUSANDS OF CELLS COMBINATIONS OF CELL SURFACE PROTEIN MARKERS, RNA ABUNDANCE AND CHROMATIN ACCESSIBILITY. THE CENTER'S TECHNOLOGY INNOVATION LABORATORY HAS COMPLETED SEVERAL PROJECTS AND IS GEARING UP TO SUPPORT MULTIPLE LARGE GRANTS IN WHICH THESE ASSAYS WILL BE APPLIED. IN ADDITION, THE LAB HAS IMPLEMENTED A NOVEL AMPLIFICATION FREE SINGLE CELL WHOLE GENOME SEQUENCING ASSAY THAT IS BEING USED IN A LARGE STUDY OF ESOPHAGEAL CANCER IN A COLLABORATION WITH COLUMBIA UNIVERSITY AND CAMBRIDGE UNIVERSITY. |
| FORM 990, PART III, LINE 4A | DIVERSITY, EQUITY, AND INCLUSION --------------------- IN 2020, NYGC LAUNCHED AN ORGANIZATION-WIDE DIVERSITY, EQUITY, AND INCLUSION INITIATIVE, AFFIRMING NYGC'S COMMITMENT TO TAKE ACTIONABLE STEPS TOWARD CREATING A COMMUNITY ENVIRONMENT THAT IS WELCOMING AND INCLUSIVE TO ALL REGARDLESS OF RACE, ETHNICITY, GENDER, SEXUAL ORIENTATION, PHYSICAL ABILITY, AGE, OR RELIGION. IN 2021, NYGC'S CROSS-FUNCTIONAL DIVERSITY, EQUITY AND INCLUSION (DEI) ADVISORY GROUP, WHOSE GOAL IS TO FOSTER AND PROMOTE DIVERSITY, EQUITY AND INCLUSION THROUGHOUT ALL ASPECTS OF NYGC'S WORK AND CULTURE, PROVIDED EDUCATION AND RESOURCES TO THE NYGC COMMUNITY TO RAISE AWARENESS OF INEQUALITY AND BIAS AND TO ENHANCE CULTURAL COMPETENCY. EXAMPLES INCLUDE BOOK CLUBS, ORGANIZATION-WIDE TRAINING ON ISSUES RELATED TO DIVERSITY AND INCLUSION, AND THE DEVELOPMENT OF A WORKPLACE CULTURE SURVEY. THE GROUP, IN CLOSE PARTNERSHIP WITH NYGC'S SENIOR TEAM, HAS SHOWCASED THE WORK AND SKILLS OF DIVERSE EMPLOYEES, STAFF, FACULTY AND TRAINEES, WITH MENTORSHIP CAREER PANELS, AND BY DEVELOPING WEB PAGES, ARTICLES AND COMMUNICATIONS ON DEI-RELATED TOPICS. IT IS ALSO WORKING TO PROMOTE AND SUPPORT AN INCLUSIVE RESEARCH AND TRAINING ENVIRONMENT, INCLUDING BY HOSTING AN INTERNSHIP PROGRAM FOR UNDER-REPRESENTED MINORITIES IN 2021. NYGC IS COMMITTED TO ADDRESSING SYSTEMIC RACISM AND INEQUALITIES IN SCIENCE AND IN THE WORKPLACE AND WILL CONTINUE TO EXPAND ITS WORK IN ALL OF THESE AREAS. |
| FORM 990, PART VI, SECTION A, LINE 6 | AS OF DECEMBER 31, 2021, THE CENTER HAD A TOTAL OF 20 MEMBERS, CONSISTING OF 12 INSTITUTIONAL FOUNDING MEMBERS AND EIGHT ASSOCIATE MEMBERS. *THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) THE JACKSON LABORATORY, (4) MEMORIAL SLOAN-KETTERING CANCER CENTER, (5) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (6) NEW YORK-PRESBYTERIAN HOSPITAL, (7) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (8) NORTHWELL HEALTH, (9) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (10) THE ROCKEFELLER UNIVERSITY, (11) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, AND (12) ALBERT EINSTEIN COLLEGE OF MEDICINE. *ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, (3) THE NEW YORK STEM CELL FOUNDATION, (4) ROSWELL PARK CANCER INSTITUTE, (5) PRINCETON UNIVERSITY, (6) HACKENSACK MERIDIAN HEALTH, (7) GEORGETOWN LOMBARDI COMPREHENSIVE CANCER CENTER, AND (8) RUTGERS CANCER INSTITUTE OF NEW JERSEY. |
| FORM 990, PART VI, SECTION A, LINE 7A | EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGC'S BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR AND OTHER DESIGNATED DIRECTORS OR INDIVIDUALS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS AND HAS THE DISCRETION TO MAKE CERTAIN DECISIONS WITHOUT FORMAL BOARD APPROVAL. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE CHIEF FINANCIAL OFFICER; DIRECTOR OF FINANCE; GENERAL COUNSEL; AND THE SCIENTIFIC DIRECTOR/CEO REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. ALSO PRIOR TO FILING, MANAGEMENT PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS. |
| FORM 990, PART VI, SECTION B, LINE 12C | NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, OFFICERS, AND KEY EMPLOYEES) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST DISCLOSED BY BOARD MEMBERS OR OFFICERS MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY PRESENT INFORMATION RELEVANT TO THE CONFLICT OF INTEREST OR UNDERLYING TRANSACTION AT A BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST. |
| FORM 990, PART VI, SECTION B, LINE 15 | FOR THE ORGANIZATION'S TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. FOR 2021, NYGC HIRED AN INDEPENDENT, OUTSIDE COMPENSATION CONSULTANT TO PERFORM AN ANALYSIS OF SENIOR MANAGEMENT'S TOTAL COMPENSATION. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO MEMBERS OF SENIOR MANAGEMENT (CHERYL MOORE, CAROL ASHE, SOREN GERMER, ELIZABETH O'BRIEN, MICHAEL ZODY, THOMAS LEHNER AND TOM MANIATIS) WAS REASONABLE. THE AD-HOC COMPENSATION COMMITTEE OF THE BOARD (WHICH IS COMPOSED OF INDEPENDENT BOARD MEMBERS) MET WITH THE OUTSIDE CONSULTANT AT A COMMITTEE MEETING HELD IN JANUARY 2021 AND APPROVED THE 2021 COMPENSATION TO BE PAID TO SENIOR MANAGEMENT. THE COMMITTEE DOCUMENTED ITS ACTIONS IN WRITTEN MEETING MINUTES. IN MID-2021, ACTING ON INFORMATION PROVIDED BY NYGC'S INDEPENDENT COMPENSATION CONSULTANT, NYGC INCREASED MICHAEL ZODY'S SALARY TO BRING IT CLOSER TO MARKET LEVELS. THIS SALARY CHANGE WAS REVIEWED AND APPROVED BY THE AD-HOC COMPENSATION COMMITTEE OF THE BOARD AND DOCUMENTED IN WRITING. IN MID-2021, CHARLES GAGNON WAS PROMOTED TO THE EXECUTIVE ROLE OF CHIEF INFORMATION OFFICER AND GIVEN A SALARY INCREASE. PRIOR TO HIS PROMOTION, NYGC OBTAINED AN INDEPENDENT COMPENSATION ANALYSIS FOR THE POSITION, CONFIRMING THAT HIS PROPOSED SALARY INCREASE WAS REASONABLE. THE INDEPENDENT COMPENSATION ANALYSIS WAS REVIEWED BY THE AD-HOC COMPENSATION COMMITTEE OF THE BOARD, WHICH APPROVED MR. GAGNON'S SALARY AND DOCUMENTED ITS DECISION IN WRITING. IN OCTOBER 2021, SARAH LESSER AVINS WAS HIRED INTO THE EXECUTIVE ROLE OF SENIOR VICE PRESIDENT, ADVANCEMENT. PRIOR TO MS. AVINS HIRE, NYGC OBTAINED AN INDEPENDENT COMPENSATION ANALYSIS FOR THE POSITION CONFIRMING THAT HER PROPOSED TOTAL COMPENSATION WAS REASONABLE. THE INDEPENDENT COMPENSATION ANALYSIS WAS REVIEWED BY THE AD-HOC COMPENSATION COMMITTEE OF THE BOARD, WHICH APPROVED MS. AVINS COMPENSATION AND DOCUMENTED ITS DECISION IN WRITING. THE SENIOR MANAGEMENT TEAM RECEIVED STANDARD MERIT INCREASES IN 2021. |
| FORM 990, PART VI, SECTION C, LINE 19 | NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. |
| FORM 990, PART VII, SECTION A | IN 2021, TOM MANIATIS, PHD., SCIENTIFIC DIRECTOR & CEO, WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR AND CEO, AN OFFICER OF THE CORPORATION, AND AN ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAMS AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. DR. MANIATIS DEVOTES 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. |
| Software ID: | |
| Software Version: |